

More than 300,000 [1] patients receive mechanical ventilation in the United States each year. It is estimated up to 40% of those patients may experience ventilator associated pneumonia (VAP). [2]

Estimated US [2] cost of ONE
Ventilator Associated Pneumonia



\$40,144

Patients who use

Biphasic Cuirass Ventilation are not exposed to the risks of Ventilator Associated Events including Ventilator Associated Pneumonia.

Avoidance of VAP by the use of BCV™ can create significant cost reductions for healthcare systems!

Since the onset of COVID-19:

89.9% rate of IMV among patients admitted to ICUs in US^[4]

VAP may occur in up to 40% of Patients [2] Mortality Rate of 29.7% of those on mechanical ventilation [3]







Biphasic Cuirass Ventilation (BCV™) can be used to expedite the weaning process in difficult to wean patients decreasing the risk of high costs associated with Prolonged Mechanical Ventilation.



=



Using
Biphasic
Cuirass
Ventilation

Decreased Intubation Rate

Less People on Mechanical Ventilation Less time on ventilation & shorter length of stay

Home Use Can Help Avoid Readmissions

If a patient suffers a chronic condition, BCV[™] is an option for home use to help prevent frequent hospitalization.

BCV™ IS A COST SAVING TOOL!

Medical Disclaimer: The content provided in Hayek Medical's educational materials are for informative purposes only and are not intended to serve as a substitute for the consultation, diagnosis, and/or medical treatment of a qualified physician or healthcare provider.

CONTACT US TODAY FOR MORE INFORMATION

1-855-243-8228 www.hayekmedical.com